Download PDF
Semin Thromb Hemost 2013; 39(04): 452-458
DOI: 10.1055/s-0033-1334145
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombolytic Therapy for Acute Pulmonary Embolism

Victor F. Tapson
1   Department of Medicine, Center for Pulmonary Vascular Disease, Duke University Medical Center, Durham, North Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
28 March 2013 (online)

   Permissions and Reprints

Abstract

Thrombolytic therapy accelerates the dissolution of acute pulmonary embolism and is potentially lifesaving. The goal of this article is to offer a critical analysis of the use of thrombolytic therapy in this setting. Guidelines have been written and modified and new ones have been published over the past several years. Although an evidence base exists, unanswered questions remain. Despite the potential benefit of rapid clot lysis, nonpathologic thrombi are also lysed, so that thrombolytic therapy can cause significant bleeding complications. Massive acute pulmonary embolism is the clearest indication for these drugs, and although thrombolysis has been studied in submassive pulmonary embolism, this scenario remains more controversial. Traditionally, thrombolytic agents have been delivered intravenously, but intraembolic therapy via a pulmonary artery catheter has gained momentum. Few randomized trials have been conducted, however. Only three agents have been approved for use in the United States: streptokinase, urokinase, and tissue-type plasminogen activator. Urokinase is not currently available for use in the United States. The latter agent has been most widely used on the basis of proven benefit with a relatively short (2-hour) infusion. Newer, unapproved agents include tenecteplase and reteplase. Risk stratification in acute pulmonary embolism is important in determining which patients are the most appropriate candidates for thrombolysis, with careful consideration of contraindications.

Keywords

pulmonary embolism - deep venous thrombosis - thrombolytic therapy - right ventricular function - catheter-based embolectomy
 

  • References

  • 1 The Urokinase Pulmonary Embolism Trial. A national cooperative study. Circulation 1973; 47 (2) (Suppl): II1-II108
    CrossrefPubMedGoogle Scholar
  • 2 Tibbutt DA, Davies JA, Anderson JA , et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism. BMJ 1974; 1 (5904) 343-347
    CrossrefPubMedGoogle Scholar
  • 3 Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203 (6) 465-470
    PubMedGoogle Scholar
  • 4 Dotter CT, Seamon AJ, Rosch J , et al. Streptokinase and heparin in the treatment of pulmonary embolism: a randomized clinical trial. Vasc Surg 1979; 13: 42-52
    PubMedGoogle Scholar
  • 5 Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54 (3) 162-173
    CrossrefPubMedGoogle Scholar
  • 6 Levine M, Hirsh J, Weitz J , et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98 (6) 1473-1479
    CrossrefPubMedGoogle Scholar
  • 7 The PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990; 97 (3) 528-533
    CrossrefPubMedGoogle Scholar
  • 8 Dalla-Volta S, Palla A, Santolicandro A , et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20 (3) 520-526
    CrossrefPubMedGoogle Scholar
  • 9 Goldhaber SZ, Haire WD, Feldstein ML , et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341 (8844) 507-511
    CrossrefPubMedGoogle Scholar
  • 10 Jerjes-Sanchez C, Ramírez-Rivera A, Arriaga-Nava R , et al; de Lourdes García M. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995; 2 (3) 227-229
    CrossrefPubMedGoogle Scholar
  • 11 Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347 (15) 1143-1150
    CrossrefPubMedGoogle Scholar
  • 12 Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343 (8893) 311-322
    PubMedGoogle Scholar
  • 13 Kearon C, Akl EA, Comerota AJ , et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S
    CrossrefPubMedGoogle Scholar
  • 14 Jaff MR, McMurtry MS, Archer SL , et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123 (16) 1788-1830
    CrossrefPubMedGoogle Scholar
  • 15 Thabut G, Thabut D, Myers RP , et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002; 40 (9) 1660-1667
    CrossrefPubMedGoogle Scholar
  • 16 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353 (9162) 1386-1389
    CrossrefPubMedGoogle Scholar
  • 17 Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2006; (2) CD004437
    PubMedGoogle Scholar
  • 18 Jiménez D, Aujesky D, Moores L , et al; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010; 170 (15) 1383-1389
    CrossrefPubMedGoogle Scholar
  • 19 Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110 (6) 744-749
    CrossrefPubMedGoogle Scholar
  • 20 Lu MT, Cai T, Ersoy H , et al. Interval increase in right-left ventricular diameter ratios at CT as a predictor of 30-day mortality after acute pulmonary embolism: initial experience. Radiology 2008; 246 (1) 281-287
    CrossrefPubMedGoogle Scholar
  • 21 Vedovati MC, Becattini C, Agnelli G , et al. Multidetector computed tomography for acute pulmonary embolism: Embolic burden and clinical outcome. Chest 2012; 142 (6) 1417-1424
    CrossrefPubMedGoogle Scholar
  • 22 Kostrubiec M, Pruszczyk P, Bochowicz A , et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26 (20) 2166-2172
    CrossrefPubMedGoogle Scholar
  • 23 Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116 (4) 427-433
    CrossrefPubMedGoogle Scholar
  • 24 Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med 2008; 34 (12) 2147-2156
    CrossrefPubMedGoogle Scholar
  • 25 Reichlin T, Hochholzer W, Bassetti S , et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361 (9) 858-867
    CrossrefPubMedGoogle Scholar
  • 26 Lankeit M, Friesen D, Aschoff J , et al. Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. Eur Heart J 2010; 31 (15) 1836-1844
    CrossrefPubMedGoogle Scholar
  • 27 Lankeit M, Jiménez D, Kostrubiec M , et al. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation 2011; 124 (24) 2716-2724
    CrossrefPubMedGoogle Scholar
  • 28 Jiménez D, Aujesky D, Moores L , et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011; 66 (1) 75-81
    CrossrefPubMedGoogle Scholar
  • 29 Jiménez D , et al. Prognostic significance of deep venous thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010; 18: 983-991
    PubMedGoogle Scholar
  • 30 Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82 (8) 966-970
    CrossrefPubMedGoogle Scholar
  • 31 PEITHO pulmonary embolism thrombolysis study. Available at: http://clinicaltrials.gov/ct2/show/NCT00639743 . Accessed January 12, 2013
    PubMedGoogle Scholar
  • 32 Becattini C, Agnelli G, Salvi A , et al; TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125 (3) e82-e86
    CrossrefPubMedGoogle Scholar
  • 33 Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358 (9282) 605-613
    CrossrefPubMedGoogle Scholar
  • 34 Kilic A, Shah AS, Conte JV, Yuh DD. Nationwide outcomes of surgical embolectomy for acute pulmonary embolism. J Thorac Cardiovasc Surg 2013; 145 (2) 373-377
    CrossrefPubMedGoogle Scholar
  • 35 Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20 (11) 1431-1440
    CrossrefPubMedGoogle Scholar
  • 36 Leacche M, Unic D, Goldhaber SZ , et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005; 129 (5) 1018-1023
    CrossrefPubMedGoogle Scholar
  • 37 Tapson VF, Gurbel PA, Witty LA, Pieper KS, Stack RS. Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy. Chest 1994; 106 (5) 1558-1562
    CrossrefPubMedGoogle Scholar
  • 38 Tapson VF. Interventional therapies for venous thromboembolism: vena caval interruption, surgical embolectomy, and catheter-directed interventions. Clin Chest Med 2010; 31 (4) 771-781
    CrossrefPubMedGoogle Scholar
  • 39 Greenfield LJ, Kimmell GO, McCurdy III WC. Transvenous removal of pulmonary emboli by vacuum-cup catheter technique. J Surg Res 1969; 9 (6) 347-352
    CrossrefPubMedGoogle Scholar
  • 40 Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Zabakis P, Hahalis G. AngioJet rheolytic thrombectomy versus local intrapulmonary thrombolysis in massive pulmonary embolism: a retrospective data analysis. J Endovasc Ther 2005; 12 (2) 206-214
    CrossrefPubMedGoogle Scholar
  • 41 Margheri M, Vittori G, Vecchio S , et al. Early and long-term clinical results of AngioJet rheolytic thrombectomy in patients with acute pulmonary embolism. Am J Cardiol 2008; 101 (2) 252-258
    CrossrefPubMedGoogle Scholar
  • 42 Engelhardt TC, Taylor AJ, Simprini LA, Kucher N. Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism. Thromb Res 2011; 128 (2) 149-154
    CrossrefPubMedGoogle Scholar
  • 43 A prospective, single-arm, multi-center trial of EkoSonic® endovascular system and activase for treatment of acute pulmonary embolism (PE). (SEATTLE II). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01513759 . Accessed January 12, 2013
    PubMedGoogle Scholar
  • 44 Todoran TM, Sobieszczyk PS, Levy MS , et al. Percutaneous extraction of right atrial mass using the Angiovac aspiration system. J Vasc Interv Radiol 2011; 22 (9) 1345-1347
    CrossrefPubMedGoogle Scholar
  • 45 Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012; 125 (5) 465-470
    CrossrefPubMedGoogle Scholar
  • 46 Tapson VF. What will it take to initiate a move toward a more aggressive therapeutic approach to venous thromboembolism?. Am J Med 2008; 121 (11) (Suppl 1): S20-S27
    PubMedGoogle Scholar